Loading...
XSHE
002755
Market cap1.95bUSD
Jul 10, Last price  
14.75CNY
1D
3.36%
1Q
-6.35%
Jan 2017
-34.71%
IPO
122.58%
Name

Beijing Aosaikang Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002755 chart
P/E
57.86
P/S
7.70
EPS
0.25
Div Yield, %
0.84%
Shrs. gr., 5y
0.39%
Rev. gr., 5y
-14.00%
Revenues
1.78b
+0.08%
529,171,4082,040,910,053488,924,723470,869,1963,011,174,5003,092,185,2003,404,858,6603,931,881,7264,518,631,6913,782,688,9113,106,666,5691,872,572,1891,443,459,6081,777,641,9111,779,025,142
Net income
237m
+47.60%
49,135,19159,954,11255,521,02537,504,227509,012,900629,984,100607,537,818670,073,627780,959,202721,625,107379,907,790-225,825,438-148,529,760160,294,271236,601,000
CFO
652m
+58.41%
33,293,245106,470,20200016,729,5320497,158,803534,615,973580,383,967567,707,6500-26,568,451411,357,064651,642,594
Dividend
Jun 16, 20250.12 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Operating within China, Beijing Aosaikang Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of pharmaceuticals, fine chemicals, and health products. Its diverse offerings include proton pump inhibitor injections, oncology medications, and active pharmaceutical ingredients (APIs), which are applied across key therapeutic areas like digestive disorders, cancer treatment, and infectious diseases. The company was founded in 2003 and is headquartered in Nanjing, China.
IPO date
May 15, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT